{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Appendix B', 'General guidance for the follow-up of laboratory abnormalities by', 'sanofi', 'Immune thrombocytopenia', 'All patients will be monitored with monthly laboratory tests. The table below summarizes the', 'minimum recommendations for ITP monitoring.', 'Summary of Minimum Recommendations for ITP Monitoring of All Patients', 'Test', 'Result', 'Action Items', 'Changes In', 'Monitoring', 'Platelet Count', '<LLN', 'Immediate repeat', 'If Repeat', 'Hematology', '<LLNWeekly', 'Hematology Until', 'Stable*', '<100,000/', 'Immediate repeat', 'If Repeat <LLN', 'L', 'Hematology;', 'Weekly Hematology', 'Hematology Consult if', 'Until Stable*', 'confirmed', '<50,000/', 'Immediate repeat', 'If Repeat <LLN', 'L', 'Hematology; Emergency', 'Weekly Hematology', 'Hematology Consult if', 'Until Stable*', 'confirmed', 'Platelet Drop (but still within normal', '100,000/', 'Investigator Notified', 'Investigator Discretion', 'range)', 'L from', 'prior', '140,000/', 'Repeat Hematology', 'If Repeat < LLN', 'L from', 'Weekly Hematology', 'prior', 'Until Stable', 'ITP Signs or Symptoms', 'Any ITP', 'Immediate site contact to', 'As outlined above', 'Signs or', 'determine further', 'Symptoms', 'evaluation', '*Weekly CBC Protocol: Weekly platelet counts for at least 8 weeks.', 'Return to Monthly when:', '- Platelet counts X 8 are within the normal range', '(or)', '- Platelet counts stabilize (8 consecutive readings >100,000/uL and average of last 4 counts average of 4 prior counts)', 'After documenting stabilization, continue monthly monitoring as long as platelet counts remain >100,000/uL; If a subsequent', 'platelet count is confirmed to be <100,000, the patient should resume weekly monitoring.', 'In addition to the above recommendations, the ongoing and long-term management of all patients', 'with ITP will be subject to the clinical judgment of the treating hematologist.', 'Property of the Sanofi Group - strictly confidential', 'Page 105', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Definition of ITP: For the purposes of this study, patients will be considered to have a diagnosis', 'of ITP if they have all of the following:', 'Normal Hgb.', 'Normal WBC, though the differential will likely reflect lymphopenia as a result of the', 'alemtuzumab treatment.', 'No splenomegaly.', 'No evidence of alternative nonautoimmune etiology of thrombocytopenia (eg,', 'cytomegalovirus [CMV] infection).', 'Normal peripheral smear except for a decrease in platelets without clumping.', 'AND either of the following:', 'A confirmed platelet count equal to or above 50,000/uL but below 100,000/L on at least', '2 consecutive occasions over a period of at least 1 month, or,', 'A confirmed platelet count below 50,000/L without clumping documented on at least', '2 consecutive occasions over any period of time.', 'It is recognized that confounding medical conditions may result in other abnormalities to the', 'CBC, which can render diagnosis more difficult. Nonetheless, any alemtuzumab-treated', 'patient who meets the ITP criteria specified immediately above will receive no further', 'alemtuzumab and will be immediately referred for hematologic consultation.', 'If upon review of the peripheral smear platelet clumping is present indicative of', 'pseudothrombocytopenia, the Hematology Panel should be repeated at a laboratory using an', 'anticoagulant other than ethylenediamine tetraacetic acid (EDTA). In addition, examination of', 'the peripheral smear should reveal a normal platelet estimate.', 'Property of the Sanofi Group - strictly confidential', 'Page 106', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}